Clinical Trials Logo

Clinical Trial Summary

Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05689229
Study type Interventional
Source Beni-Suef University
Contact
Status Completed
Phase Phase 3
Start date August 3, 2021
Completion date December 12, 2021